ABEMACICLIB

Information current as at: 1 November 2024

The pharmaceutical company has advised that it is not proceeding in the PBS listing process at this time. The process for listing this medicine has ceased.


Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Verzenio™
Pharmaceutical company:
Eli Lilly Australia Pty Ltd
Condition/indication:
(therapeutic use)
  • Breast cancer
PBAC Submission type:
Change to PBS listing (Standard Re-entry Pathway)
Comment:
No further action, please see ABEMACICLIB link in Related medicines below.
Public Summary Document:
PBAC Public Summary Documents – March 2023
Related medicines:

Progress Details

Submission received for:
March 2023 PBAC meeting
Opportunity for consumer comment:
Open 23/11/2022 and close 25/01/2023 (see PBS Website)
PBAC meeting:
Held on 08/03/2023
PBAC outcome published:
Recommended (see PBAC Outcomes)
Notice of intent submitted:
28/04/2023
Lodgement of required documentation:
Not applicable
Agreement to listing arrangements:
Not applicable
Government processes:
Not applicable
Medicine listed on the PBS:
Not applicable
Glossary

Case ID: a627

Page last updated: 31 October 2024

Return to the Medicine Status Listing
v.9.18